Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Lowers 2010 Guidance Due To U.S. Health Care Reform; Q1 Sales Rise 14.6%

This article was originally published in The Pink Sheet Daily

Executive Summary

Abbott adjusted its previous 2010 earnings per share guidance by $0.07 to range from $4.13 to $4.18.

You may also be interested in...



Health Care Reform's Impact Reflected In Pharma's Q1 Results

President Obama had barely put his signature to the new health care reform law when its impact on biopharma became clear. With Lilly in the lead, a parade of companies posted first quarter financial results which underscored a key point for the industry: it is bearing costs of the new law immediately, but won't reap the benefits for several years

Health Care Reform's Impact Reflected In Pharma's Q1 Results

President Obama had barely put his signature to the new health care reform law when its impact on biopharma became clear. With Lilly in the lead, a parade of companies posted first quarter financial results which underscored a key point for the industry: it is bearing costs of the new law immediately, but won't reap the benefits for several years

Lilly Slashes Revenue Forecasts For 2010 And 2011 Due To Health Care Reform

The drug maker blames changes to various government programs for revenue that will drop by hundreds of millions of dollars.

Topics

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel